SE464168B - Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt) - Google Patents

Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)

Info

Publication number
SE464168B
SE464168B SE8902568A SE8902568A SE464168B SE 464168 B SE464168 B SE 464168B SE 8902568 A SE8902568 A SE 8902568A SE 8902568 A SE8902568 A SE 8902568A SE 464168 B SE464168 B SE 464168B
Authority
SE
Sweden
Prior art keywords
compound
azt
fluoro
flt
composition according
Prior art date
Application number
SE8902568A
Other languages
English (en)
Swedish (sv)
Other versions
SE8902568L (sv
SE8902568D0 (sv
Inventor
Bo Fredrik Oeberg
Britta Wahren
Johan Georg Harmenberg
Original Assignee
Bo Fredrik Oeberg
Britta Wahren
Johan Georg Harmenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bo Fredrik Oeberg, Britta Wahren, Johan Georg Harmenberg filed Critical Bo Fredrik Oeberg
Priority to SE8902568A priority Critical patent/SE464168B/sv
Publication of SE8902568D0 publication Critical patent/SE8902568D0/xx
Priority to JP51055190A priority patent/JP3149179B2/ja
Priority to AT90911382T priority patent/ATE132752T1/de
Priority to AU60469/90A priority patent/AU630220B2/en
Priority to DE69024804T priority patent/DE69024804T2/de
Priority to PCT/SE1990/000487 priority patent/WO1991001137A1/fr
Priority to CA002063417A priority patent/CA2063417C/fr
Priority to ES90911382T priority patent/ES2083458T3/es
Priority to EP90911382A priority patent/EP0482081B1/fr
Priority to DK90911382.1T priority patent/DK0482081T3/da
Publication of SE8902568L publication Critical patent/SE8902568L/xx
Publication of SE464168B publication Critical patent/SE464168B/sv
Priority to US08/354,891 priority patent/US5571798A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE8902568A 1989-07-19 1989-07-19 Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt) SE464168B (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE8902568A SE464168B (sv) 1989-07-19 1989-07-19 Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
DK90911382.1T DK0482081T3 (da) 1989-07-19 1990-07-10 Antiviralt præparat
DE69024804T DE69024804T2 (de) 1989-07-19 1990-07-10 Antivirale zusammensetzung
AT90911382T ATE132752T1 (de) 1989-07-19 1990-07-10 Antivirale zusammensetzung
AU60469/90A AU630220B2 (en) 1989-07-19 1990-07-10 Antiviral composition
JP51055190A JP3149179B2 (ja) 1989-07-19 1990-07-10 抗ウイルス組成物
PCT/SE1990/000487 WO1991001137A1 (fr) 1989-07-19 1990-07-10 Composition antivirale
CA002063417A CA2063417C (fr) 1989-07-19 1990-07-10 Composition antivirale
ES90911382T ES2083458T3 (es) 1989-07-19 1990-07-10 Composicion antivirica.
EP90911382A EP0482081B1 (fr) 1989-07-19 1990-07-10 Composition antivirale
US08/354,891 US5571798A (en) 1989-07-19 1994-12-09 Synergistic antiviral nucleoside combinations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8902568A SE464168B (sv) 1989-07-19 1989-07-19 Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)

Publications (3)

Publication Number Publication Date
SE8902568D0 SE8902568D0 (sv) 1989-07-19
SE8902568L SE8902568L (sv) 1991-01-20
SE464168B true SE464168B (sv) 1991-03-18

Family

ID=20376569

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8902568A SE464168B (sv) 1989-07-19 1989-07-19 Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)

Country Status (11)

Country Link
US (1) US5571798A (fr)
EP (1) EP0482081B1 (fr)
JP (1) JP3149179B2 (fr)
AT (1) ATE132752T1 (fr)
AU (1) AU630220B2 (fr)
CA (1) CA2063417C (fr)
DE (1) DE69024804T2 (fr)
DK (1) DK0482081T3 (fr)
ES (1) ES2083458T3 (fr)
SE (1) SE464168B (fr)
WO (1) WO1991001137A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE138927T1 (de) * 1990-08-06 1996-06-15 American Cyanamid Co Verfahren zur herstellung von desoxynukleosiden
JPH06502155A (ja) * 1990-10-30 1994-03-10 ザ　ウエルカム　ファウンデーション　リミテッド 脱髄性疾患の処置方法
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
WO1992020344A1 (fr) † 1991-05-16 1992-11-26 Glaxo Group Limited Combinaisons antivirales contenant des analogues de nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5760013A (en) * 1996-08-21 1998-06-02 National Science Council Thymidylate analogs and the use thereof
US5925514A (en) * 1996-12-10 1999-07-20 The Regents Of The University Of California Apparatus for testing for infection by a retrovirus
US5968731A (en) * 1996-12-10 1999-10-19 The Regents Of The University Of California Apparatus for automated testing of biological specimens
US5841975A (en) * 1996-12-10 1998-11-24 The Regents Of The University Of California Method and apparatus for globally-accessible automated testing
DE19832519A1 (de) * 1998-07-20 2000-01-27 Hartmut Oswald Arzneimittelzubereitungen zur topischen Behandlung mukokutaner Herpesinfektionen sowie der Keratitis herpetica des Auges
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
ES2254941T3 (es) * 2002-06-27 2006-06-16 Medivir Ab Interaccion sinergica entre abacavir y alovudina.
WO2004087140A1 (fr) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Combinaison antivirale d'une dipyridodiazepinone et compose antiretroviral
WO2004087169A1 (fr) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Combinaison antivirale de nevirapine et d'un autre compose antiretroviral
WO2004087139A1 (fr) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Combinaison antivirale de tipranavir et d'un autre compose antiretroviral
EP1937825B1 (fr) * 2005-09-26 2016-12-21 Gilead Pharmasset LLC 4'-nucleosides modifies en tant qu'agents antiviraux
GB0608876D0 (en) * 2006-05-05 2006-06-14 Medivir Ab Combination therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
WO1987001284A1 (fr) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition du caractere infectieux et de l'effet cytopathique du htlv-iii/lav in vitro par la 2',3'-dideoxyinosine, 2',3'-dideoxyguanosine, ou 2',3'-dideoxyadenosine
US4681933A (en) * 1986-05-01 1987-07-21 University Of Georgia Research Foundation, Inc. 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
EP0286825A3 (fr) * 1987-03-18 1989-04-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Utilisation du 3'-fluro-3'-deoxythymidine pour fabriquer un médicament pour le traitement des infections virales
US4908440A (en) * 1987-11-12 1990-03-13 Bristol Myers Company 2',3'-dideoxy-2'-fluoroarabinopyrimidine nucleosides
US4904770A (en) * 1988-03-24 1990-02-27 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
US5122517A (en) * 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
US5059418A (en) * 1989-09-20 1991-10-22 The Administrators Of The Tulane Educational Fund Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination

Also Published As

Publication number Publication date
SE8902568L (sv) 1991-01-20
DE69024804T2 (de) 1996-08-29
SE8902568D0 (sv) 1989-07-19
AU6046990A (en) 1991-02-22
AU630220B2 (en) 1992-10-22
CA2063417A1 (fr) 1991-01-20
DK0482081T3 (da) 1996-05-28
ES2083458T3 (es) 1996-04-16
JP3149179B2 (ja) 2001-03-26
ATE132752T1 (de) 1996-01-15
US5571798A (en) 1996-11-05
JPH04506961A (ja) 1992-12-03
EP0482081B1 (fr) 1996-01-10
WO1991001137A1 (fr) 1991-02-07
DE69024804D1 (de) 1996-02-22
CA2063417C (fr) 2000-12-12
EP0482081A1 (fr) 1992-04-29

Similar Documents

Publication Publication Date Title
SE464168B (sv) Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
Balzarini et al. 9-(2-Phosphonylmethoxyethyl) adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys
KR100454663B1 (ko) 프로테아제억제제에기초한요법에서세포내프로테아제억제제의흡수를증가시키기위한제약조성물
Gustafson et al. AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae)
Fauci et al. The acquired immunodeficiency syndrome: an update
US8158575B2 (en) Agent for the prevention and treatment of sexually transmitted diseases-I
Koshida et al. Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1
Connolly et al. Antiretroviral therapy: reverse transcriptase inhibition
Busso et al. Nucleotide dimers suppress HIV expression in vitro
CA1339854C (fr) Systeme de traitement des infections virales
US5084445A (en) 3'-azido-2',3'-dideoxy-5-methylcytidine
Fujiwara et al. Ingenol derivatives are highly potent and selective inhibitors of HIV replication in vitro
Baba et al. Selective inhibition of human immunodeficiency virus type 1 replication by novel fluoroalkylated oligomers in vitro
De Simone et al. Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study
Zeidner et al. Zidovudine in combination with alpha interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS)
EP0286825A2 (fr) Utilisation du 3'-fluro-3'-deoxythymidine pour fabriquer un médicament pour le traitement des infections virales
SK168196A3 (en) Anti-hiv triple combination
WO2002059123A2 (fr) Composes benzoylalkylindolepyridinium et compositions pharmaceutiques comprenant ces composes
Richman The Treatment of HIV Infection: Azidothymidine (AZT) and Other New Antiviral Drugs
Nakashima et al. Sulfated alkyl oligosaccharides inhibit human immunodeficiency virus in vitro and provide sustained drug levels in mammals
US20040110774A1 (en) Methods and formulations of using A1 adenosine receptor antagonists and P2x purinoceptor antagonists for the treatment and prevention of immune system disorders
US20020182151A1 (en) Benzoylalkylindolepyridinium componds and pharmaceutical compositions comprising such compounds
Broom et al. Unusual single-stranded polyribonucleotides as potent anti-HIV agents
EP1545539A2 (fr) Compositions permettant d'induire des niveaux accrus de g(b)-chimiokines et methodes d'utilisation associees
BHAT et al. Benzopurpurin and related compounds inhibit the binding of gp120 to galactosyl ceramide/sulfatide and infection of human immunodeficiency virus

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8902568-8

Format of ref document f/p: F

NUG Patent has lapsed